Arvinas News

Analysts' Top Healthcare Picks: Quanterix (QTRX), Intuitive Surgical (ISRG)

TipRanksApr 16 14:40

HC Wainwright & Co. : The Arvinas (ARVN.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $90.00 to $87.00.

Zhitong FinanceApr 15 19:30

Arvinas Analyst Ratings

BenzingaApr 15 19:24

HC Wainwright & Co. Maintains Buy on Arvinas, Lowers Price Target to $87

BenzingaApr 15 19:28

Piper Sandler Sticks to Their Buy Rating for Arvinas Holding Company (ARVN)

TipRanksApr 12 20:29

Arvinas Analyst Ratings

BenzingaApr 12 19:14

Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Arvinas Holding Company (ARVN) and Viridian Therapeutics (VRDN)

TipRanksApr 12 19:10

Buy Rating Affirmed for Arvinas Amid Strategic Novartis Deal and Growth Potential

TipRanksApr 12 01:05

Wedbush Adjusts Arvinas' Price Target to $57 From $59, Keeps Outperform Rating

MT NewswiresApr 12 00:11

Arvinas Analyst Ratings

BenzingaMar 26 00:04

Truist Securities Reiterates Buy on Arvinas, Maintains $65 Price Target

BenzingaMar 26 00:05

Arvinas Holding Company: A Buy Rating on Strong Clinical Pipeline and Promising Trial Outcomes

TipRanksMar 1 13:58

Barclays Maintains Overweight on Arvinas, Raises Price Target to $60

BenzingaFeb 29 22:04

Arvinas Holding Company: Buy Rating Backed by Promising Breast Cancer Therapy and Strategic Expansion Into Parkinson's Disease Treatment

TipRanksFeb 28 20:36

Oppenheimer Reiterates Outperform on Arvinas, Lowers Price Target to $80

BenzingaFeb 28 20:34

Arvinas Analyst Ratings

BenzingaFeb 28 20:32

Buy Rating Affirmed for Arvinas Holding Company Amid Strong Drug Candidate Prospects and Robust Financial Health

TipRanksFeb 28 18:40

Arvinas Holding Company: A Strong Buy on Robust Clinical Data and Strategic Trial Advancements

TipRanksFeb 28 04:46

Arvinas Analyst Ratings

BenzingaFeb 16 00:02

Citi Downgrades Arvinas to Neutral, Cites Valuation

Seeking AlphaFeb 15 04:55